JPRN-UMIN000034362招募中未知
Safety and efficacy of Tenofovir alafenamide (TAF) in patients with chronic hepatitis B and cirrhosis. - Safety and efficacy of Tenofovir alafenamide (TAF)
ippon Medical Chiba Hokusoh Hospital0 个研究点目标入组 500 人开始时间: 2018年10月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients who has allergy to this drugs. 2.Patients with severe kidney disease. 3.Patients who are taking Tenofovir. 4.Patients who are pregnant or breast-feeding. 5.Patients who are judged ineligible by atending physician.
研究者
相似试验
招募中
不适用
Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patientsChronic hepatitis BJPRN-UMIN000029099Toranomon branch Hospital650
进行中（未招募）
1 期
Safety of tenofovir alafenamide (TAF) in patients who developed kidney toxicity while receiving tenofovir disoproxil fumarate (TDF)HIV infectionMedDRA version: 20.1Level: PTClassification code 10020161Term: HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003345-29-GBKings College Hospital NHS Foundation Trust40
进行中（未招募）
不适用
Could the new HIV-drug TAF reduce inflammation inside the central nervous system?EUCTR2015-004427-31-SEGothenburg University
Unknown
4 期
Tenofovir Alafenamide to Prevent Perinatal Transmission of Hepatitis BChronic Hepatitis BMother-to-Child TransmissionSafetyEfficacyHepatitis B VirusTenofovir Alafenamide FumarateNCT04850950The First Affiliated Hospital of Zhengzhou University240
招募中
不适用
ong term efficacy and safety of tenofovir alafenamide fumarate (TAF) in patients with chronic hepatitis B virus(HBV) infections: an observational, non-interventional trial (TOUGH trial)B18.1Chronic viral hepatitis B without delta-agentDRKS00017414niversitätsklinikum Leipzig200